• <thead id="vs5lr"><address id="vs5lr"></address></thead>
      <th id="vs5lr"><option id="vs5lr"></option></th>
      
      
      1. <code id="vs5lr"><small id="vs5lr"></small></code>
        <code id="vs5lr"><small id="vs5lr"><optgroup id="vs5lr"></optgroup></small></code>
        1. <th id="vs5lr"><option id="vs5lr"></option></th>

          <th id="vs5lr"></th>
          <code id="vs5lr"><nobr id="vs5lr"></nobr></code>

        2. <object id="vs5lr"><video id="vs5lr"><samp id="vs5lr"></samp></video></object>
          <tr id="vs5lr"></tr>

            <thead id="vs5lr"><option id="vs5lr"></option></thead>
            <tr id="vs5lr"></tr>
          1. <big id="vs5lr"></big>
          2. <code id="vs5lr"><small id="vs5lr"><track id="vs5lr"></track></small></code>
            中文版    |    English
              Tel +86-571-88737065   QQ Online

            Company profile

            Established by senior chemists and marketing experts in Hangzhou, SYNBEST (SYNBEST) is specialized manufacturer of fine chemicals which are widely applied in pharmaceuticals, argochemicals, electronic chemicals, nutrition, cosmetics and surfactants.

            SYNBEST's head-office is in Hangzhou, Zhejiang Province, which is only 1.5 hours from Shanghai. Our R&D center covers 500M2 with advanced equipments and various analysis methods in Science and Technology Park of Hangzhou Normal University.

            Our Product

            Established by senior chemists and marketing experts in Hangzhou, SYNBEST (SYNBEST) is specialized manufacturer of fine chemicals which are widely applied in pharmaceuticals, argochemicals, electronic chemicals, nutrition, cosmetics and surfactants.

            Company News

            - 2019-07-05

            FDA Approves Xpovio

              FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

            - 2019-07-04

            New synthetic technology for medicines and fine chemicals

              A University of Tokyo research group has succeeded in synthesizing (R)- and (S)-rolipram, the active component of

            Online services
            Tel
            +86-571-88737065